- Home
- SCLXW vs DCOMP Comparison
SCLXW vs DCOMP Comparison
Compare SCLXW & DCOMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- DCOMP
- Stock Information
- Founded
- SCLXW N/A
- DCOMP N/A
- Country
- SCLXW United States
- DCOMP United States
- Employees
- SCLXW 115
- DCOMP 887
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- DCOMP Major Banks
- Sector
- SCLXW Health Care
- DCOMP Finance
- Exchange
- SCLXW Nasdaq
- DCOMP Nasdaq
- Market Cap
- SCLXW N/A
- DCOMP N/A
- IPO Year
- SCLXW N/A
- DCOMP N/A
- Fundamental
- Price
- SCLXW $0.10
- DCOMP $17.64
- Analyst Decision
- SCLXW
- DCOMP
- Analyst Count
- SCLXW 0
- DCOMP 0
- Target Price
- SCLXW N/A
- DCOMP N/A
- AVG Volume (30 Days)
- SCLXW 4.0K
- DCOMP N/A
- Earning Date
- SCLXW 03-07-2025
- DCOMP N/A
- Dividend Yield
- SCLXW N/A
- DCOMP N/A
- EPS Growth
- SCLXW N/A
- DCOMP N/A
- EPS
- SCLXW N/A
- DCOMP N/A
- Revenue
- SCLXW $55,152,000.00
- DCOMP N/A
- Revenue This Year
- SCLXW N/A
- DCOMP N/A
- Revenue Next Year
- SCLXW N/A
- DCOMP N/A
- P/E Ratio
- SCLXW N/A
- DCOMP N/A
- Revenue Growth
- SCLXW 22.02
- DCOMP N/A
- 52 Week Low
- SCLXW $0.18
- DCOMP N/A
- 52 Week High
- SCLXW $0.18
- DCOMP N/A
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- DCOMP 37.00
- Support Level
- SCLXW N/A
- DCOMP $17.05
- Resistance Level
- SCLXW N/A
- DCOMP $18.41
- Average True Range (ATR)
- SCLXW 0.00
- DCOMP 0.54
- MACD
- SCLXW 0.00
- DCOMP -0.12
- Stochastic Oscillator
- SCLXW 0.00
- DCOMP 24.28
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About DCOMP Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.